Xeris Biopharma Holdings
ISIN US98422E1038
|WKN A3C4ZC
| Is 2025 your year to invest? Explore Invesco ETFs. Capital at risk. Overview
Description
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals United States
Financials
Key metrics
| Market capitalisation, EUR | 501.33 m |
| EPS, EUR | -0.40 |
| P/B ratio | 110.04 |
| P/E ratio | - |
| Dividend yield | 0.00% |
Income statement (2023)
| Revenue, EUR | 151.62 m |
| Net income, EUR | -57.58 m |
| Profit margin | -37.98% |
What ETF is Xeris Biopharma Holdings in?
There are 6 ETFs which contain Xeris Biopharma Holdings. All of these ETFs are listed in the table below. The ETF with the largest weighting of Xeris Biopharma Holdings is the L&G Pharma Breakthrough UCITS ETF.
| ETF | Weight | Investment focus | Holdings | TER | Fund size (in m EUR) | Return 1Y | WKN | ISIN |
|---|---|---|---|---|---|---|---|---|
| L&G Global Thematic ESG Exclusions UCITS ETF USD Accumulating | 0.63% | Equity World Social/Environmental Innovation | 368 | 0.60% | 4 | +15.56% | A3DHPA | IE000VTOHNZ0 |
| iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 0.05% | Equity United States Health Care Biotech | 213 | 0.35% | 30 | +5.76% | A2JDYM | IE00BDZVHG35 |
| iShares Nasdaq US Biotechnology UCITS ETF | 0.05% | Equity United States Health Care Biotech | 213 | 0.35% | 433 | +5.49% | A2DWAW | IE00BYXG2H39 |
| Xtrackers Russell 2000 UCITS ETF 1C | 0.02% | Equity United States Small Cap | 1,490 | 0.30% | 2,063 | +22.92% | A1XEJT | IE00BJZ2DD79 |
| SPDR Russell 2000 US Small Cap UCITS ETF | 0.02% | Equity United States Small Cap | 1,797 | 0.30% | 4,771 | +23.02% | A1XFN1 | IE00BJ38QD84 |
| L&G Pharma Breakthrough UCITS ETF | 3.46% | Equity World Health Care Innovation | 37 | 0.49% | 17 | +2.62% | A2H9XR | IE00BF0H7608 |
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.